Press Releases

Dated: Friday 31 July 2009

Since Alizyme plc and Alizyme Therapeutics Limited entered administration on Monday 27 July, the administrators, Ian Carr and Nigel Morrison, partners at Grant Thornton UK LLP, have been approached by a number of parties interested in acquiring certain of the companies' products.

Ian Carr said: "We are actively talking to a number of parties regarding their possible purchase of cetilistat, a product designed to address obesity, which has completed Phase II development in the West and is in Phase III development in Japan."

"We are also talking to a number of parties with regard to the sale of ATL-104, a product for the prevention of mucositis during cancer therapy, that has demonstrated 'proof of concept' in a Phase IIa clinical study."

Anyone interested in discussing the acquisition of these products and the associated intellectual property should contact Ian Carr on 01223 225600.


For more information contact Cathy Connan on 07976 669089 or email cathy@cathyconnan.com.


Grant Thornton UK LLP is a leading financial and business adviser with 30 locations nationwide. We are the UK member of Grant Thornton International, one of the world's leading international organisations of independently owned and managed accounting and consulting firms. Although Grant Thornton International is not a worldwide partnership, the firms share a commitment to providing the same high quality service to their clients wherever they do business.

Copyright © 2009 Grant Thornton UK LLP. All rights reserved.

Grant Thornton - advisers to the independently minded – www.grantthornton.co.uk